SCHEMBL24434855

SCHEMBL24434855

CC(C)OC(C)(C)c1csc(NC(=O)c2cccn2CCCc2cccnc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 3/20 0.38
HPGD P15428 3/20 0.38
RAB9A P51151 3/20 0.38
POLB P06746 2/20 0.38
PKM P14618 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24434617 0.91 SMN1; SMN2 (0.42) SMN1; SMN2NPC1HPGDRAB9APOLB
SCHEMBL24434549 0.91 MEN1 (0.46) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL24434540 0.90 SCN3A (0.41) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL24434692 0.89 SMN1; SMN2 (0.42) SMN1; SMN2NPC1HPGDRAB9APOLB
SCHEMBL31466384 0.87 SMN1; SMN2 (0.37) SMN1; SMN2NPC1HPGDRAB9APOLB
SCHEMBL24434812 0.87 SMN1; SMN2 (0.37) SMN1; SMN2NPC1HPGDRAB9APOLB
SCHEMBL24434757 0.86 SMN1; SMN2 (0.44) SMN1; SMN2NPC1HPGDRAB9APOLB
SCHEMBL24435049 0.83 NPC1 (0.39) SMN1; SMN2NPC1HPGDRAB9APOLB
SCHEMBL31466381 0.83 NPC1 (0.39) SMN1; SMN2NPC1HPGDRAB9APOLB
SCHEMBL24434598 0.83 SMN1; SMN2 (0.39) SMN1; SMN2NPC1HPGDRAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3930849-B1 THIAZOLE DERIVATIVES AS PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2025-02-19 EP disclosed
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G HDAC3 4526/4885HDAC4 4639/4885HDAC1 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.